用于治疗阿尔茨海默病的抗淀粉样蛋白疗法——我们走在正确的道路上吗？ - Suppr

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

作者信息

Karran Eric, Hardy John

机构信息

From Reta Lila Weston Laboratories and the Department of Molecular Neuroscience, University College London, London (E.K., J.H.), and Alzheimer's Research UK, Cambridge (E.K.) - both in the United Kingdom.

出版信息

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

DOI:10.1056/NEJMe1313943

PMID:24450897

Abstract

摘要

相似文献

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.

Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.

Manag Care. 2015 Jun;24(6):19.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.

J Neurosci. 2017 Apr 26;37(17):4430-4432. doi: 10.1523/JNEUROSCI.0420-17.2017.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

引用本文的文献

Deuterium trafficking, mitochondrial dysfunction, copper homeostasis, and neurodegenerative disease.

Front Mol Biosci. 2025 Jul 22;12:1639327. doi: 10.3389/fmolb.2025.1639327. eCollection 2025.

Exploring the Neuroprotective Properties of Celery ( Linn) Extract Against Amyloid-Beta Toxicity and Enzymes Associated with Alzheimer's Disease.

Molecules. 2025 May 16;30(10):2187. doi: 10.3390/molecules30102187.

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease.

Nat Med. 2025 May;31(5):1604-1616. doi: 10.1038/s41591-025-03574-1. Epub 2025 Mar 6.

Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.

Alzheimers Dement. 2025 Jan;21(1):e14291. doi: 10.1002/alz.14291. Epub 2024 Dec 18.

The Impact of Aging on Neurological Diseases in the Elderly: Molecular Mechanisms and Therapeutic Perspectives.

Aging Dis. 2024 Nov 5;16(5):2953-2978. doi: 10.14336/AD.2024.1085.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.

Alzheimer's disease and its treatment-yesterday, today, and tomorrow.

Front Pharmacol. 2024 May 24;15:1399121. doi: 10.3389/fphar.2024.1399121. eCollection 2024.

Role of Amyloid Beta in Neurodegeneration and Therapeutic Strategies for Neuroprotection.

Methods Mol Biol. 2024;2761:337-354. doi: 10.1007/978-1-0716-3662-6_25.

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.

Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.

Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges.

Aging Dis. 2022 Dec 1;13(6):1745-1758. doi: 10.14336/AD.2022.0412.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

作者信息

Karran Eric, Hardy John

机构信息

出版信息

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

DOI:10.1056/NEJMe1313943

PMID:24450897

Abstract

摘要

相似文献

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.

[Do antibodies provide advantages for the therapy of Alzheimer's disease? Solanezumab: the jury is still out].

Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892. Epub 2014 Feb 25.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.

Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.

Manag Care. 2015 Jun;24(6):19.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.

Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.

J Neurosci. 2017 Apr 26;37(17):4430-4432. doi: 10.1523/JNEUROSCI.0420-17.2017.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

引用本文的文献

Deuterium trafficking, mitochondrial dysfunction, copper homeostasis, and neurodegenerative disease.

Front Mol Biosci. 2025 Jul 22;12:1639327. doi: 10.3389/fmolb.2025.1639327. eCollection 2025.

Exploring the Neuroprotective Properties of Celery ( Linn) Extract Against Amyloid-Beta Toxicity and Enzymes Associated with Alzheimer's Disease.

Molecules. 2025 May 16;30(10):2187. doi: 10.3390/molecules30102187.

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease.

Nat Med. 2025 May;31(5):1604-1616. doi: 10.1038/s41591-025-03574-1. Epub 2025 Mar 6.

Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.

Alzheimers Dement. 2025 Jan;21(1):e14291. doi: 10.1002/alz.14291. Epub 2024 Dec 18.

The Impact of Aging on Neurological Diseases in the Elderly: Molecular Mechanisms and Therapeutic Perspectives.

Aging Dis. 2024 Nov 5;16(5):2953-2978. doi: 10.14336/AD.2024.1085.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.

Alzheimer's disease and its treatment-yesterday, today, and tomorrow.

Front Pharmacol. 2024 May 24;15:1399121. doi: 10.3389/fphar.2024.1399121. eCollection 2024.

Role of Amyloid Beta in Neurodegeneration and Therapeutic Strategies for Neuroprotection.

Methods Mol Biol. 2024;2761:337-354. doi: 10.1007/978-1-0716-3662-6_25.

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.

Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.

Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges.

Aging Dis. 2022 Dec 1;13(6):1745-1758. doi: 10.14336/AD.2022.0412.

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

作者信息

机构信息

出版信息

相似文献

引用本文的文献